A team of scientists, including researchers from University College London (UCL), has discovered key differences in how four ...

A team of scientists including UCL researchers has tested four anti-amyloid Alzheimer's therapeutics to find out how the ...

Alzinova AB (publ) (ticker: ALZ) is pleased to announce the release of the drug substance for its upcoming Phase 2 clinical trial of the vaccine candidate ALZ-101 in early Alzheimer's disease. This mi ...

A team of scientists including UCL researchers has tested four anti-amyloid Alzheimer's therapeutics to find out how the ...

NU-9 targets a shared underlying mechanism found in various neurodegenerative diseases. A new study from Northwestern ...

At the 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (ADPD), Promis Neurosciences Inc. presented the rational design of an Alzheimer’s ...

(NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today ...

While misfolded SOD1 proteins (among others) cause ALS, misfolded amyloid beta oligomers cause Alzheimer's disease. "These are good proteins gone bad," Klein said. "They are good proteins, but when ...

Patients carrying 2 copies of the APOE4 gene (APOE4/4 homozygotes) are more likely to develop AD earlier in life than those without APOE4.

ProMIS Neurosciences as we reached a major milestone with the initiation of our 100-patient Phase 1b clinical trial for PMN310, our lead an ...